Core Viewpoint - A class action lawsuit has been filed against Viatris Inc. for allegedly providing misleading information regarding the FDA's warning letter related to its Indore, India facility, which impacted the company's operations [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Viatris securities between August 8, 2024, and February 26, 2025 [1]. - Investors have until June 3, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations - The complaint claims that Viatris misrepresented the significance of the FDA's warning letter, downplaying it as a "minor headwind" for the company [2].

NEW YORK, April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=141957&from=4CLASS PERIOD: August 8, 2024 to Februar ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Viatris between August 8, 2024 and February 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 09, 2025 (GLO ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Viatris between August 8, 2024 and February 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 09, 2025 (GLO ...

Core Viewpoint - Viatris Inc. is facing a securities class action lawsuit for failing to disclose material information during the Class Period, which has led to significant financial losses for investors [3]. Group 1: Lawsuit Details - Investors who purchased Viatris securities between August 8, 2024, and February 26, 2025, have until June 3, 2025, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Western District of Pennsylvania [1]. - The case is identified as Quinn v. Viatris Inc., et al., No. 25-cv-466 [4]. Group 2: Financial Impact - On February 27, 2025, Viatris announced disappointing fiscal 2025 guidance, attributing it to the expected financial impact from an Indore facility warning letter and import alert [4]. - Following this announcement, Viatris' stock price dropped from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025, indicating a significant loss in market value [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent boutique securities litigation law firm, is representing the investors in this case [5]. - The firm has a strong track record, being ranked among the top 10 firms nationally based on total settlement value [5].

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. due to alleged misrepresentation of the impact of a warning letter from the FDA regarding its Indore, India facility, which led to a significant decline in stock price following disappointing financial results [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Viatris securities between August 8, 2024, and February 26, 2025 [1]. - The complaint claims that the defendants misrepresented the severity of the FDA's warning letter, downplaying it as a "minor headwind" for the company [2]. - Following the announcement of disappointing fiscal 2025 guidance attributed to the warning letter and import alert, Viatris' stock price fell from $11.24 to $9.53, a decline of approximately 15.21% in one day [2]. Group 2: Investor Information - Investors who acquired shares of Viatris are encouraged to contact the law firm before the lead plaintiff motion deadline on June 3, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation [3].

Viatris, Inc. (VTRS) announced that it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.Per the terms of the settlement agreement, Viatris would pay up to a maximum of $335 million to all the above-mentioned parties. This sum consists of annual payments of approximately $27.5-$40 million to each party over a period of nine years to help support state and local efforts to address opioid-related i ...

NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form- ...

SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025. Viatris is a global healthcare company that supplies medicines to patients across more than 165 countries and territories via its 26 manufacturing and packaging sites worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give ...

ATLANTA, April 07, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Viatris Inc. (“Viatris” or “the Company”) (NASDAQ: VTRS). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts regarding the impact of the FDA’s Warning Letter on Viatris’ financials. If you bought shares of Viatris between August 8, 2024 and February 26, 2025, and you suffered a significant loss on that investment, you are e ...